Based on Audited Consolidated Financial Statements for the Year Ended on December 31, 2008, PT Kalbe Farma Tbk. and subsidiaries (“The Company”) has achieved net sales of Rp 7.9 Trillion, 12.5% higher compared to Rp 7.0 Trillion in 2007.The Company’s gross profit reached Rp 3.8 Trillion in 2008, an increase of 7.1% compared to the previous year figure. Due to increase of raw material prices and depreciation of Rupiah against USD, the Company’s gross profit margin has declined to 48.3% from the the previous year figure of 50.7%.
The Company’s operating expenses in 2008 was Rp 2.7 Trillion, or 9.9% higher than the previous year. The largest component of operating expenses was selling expenses of Rp 2.1 Trillion, followed by general and administration expenses of Rp 453 Billion and research and development expenses of Rp 54 Billion. Operating expenses ratio to net sales decreased 0.8% to 33.8% in 2008 compared to 34.6% in 2007.
In 2008, the Company was able to maintain its net income amounting to Rp 707 Billion, an increase of 0.2% compared to Rp 706 Billion in 2007.
The details of each Division performance are as follows:
* Prescription Pharmaceuticals Division, as the main business division of the Company, contributed 27.1% of the total net sales. In 2008, the division reported net sales of Rp 2,131 Billion, 18.0% higher than the previous year.
* Consumer Health Division net sales contributed 20,9% of the total net sales. The division reported net sales of Rp 1,648 Billion. As sales of Energy Drink has not yet recovered in 2008, this division net sales has been down by 11.2% compared to that of previous year.
* Nutritionals Division, the Company’s fastest growing division, contributed 24.5% of the total net sales. This division has successfully achieved its net sales of Rp 1,927 Billion or grew 20.5% compared to Rp 1,600 Billion in 2007.
* Distribution and Packaging Division also made significant contribution to total net sales at 27.5%. This division successfully reported net sales of Rp 2,170 Billion with the highest sales growth of 24.5% in 2008 compared to the previous year.
At the end of 2008, the Company increased its net income per share to Rp 72, grew 2.9% compared to Rp 70 in 2007.
This information will be available on the Company’s website at www.kalbe.co.id or for further information please contact:
Vidjongtius / Corporate Secretary
PT Kalbe Farma Tbk.
Gedung KALBE
Jl. Let. Jend. Suprapto Kav. 4
Cempaka Putih – Jakarta
Phone: (021) 428-73688
Fax : (021) 428-73678
Email : vidjongtius@kalbe.co.id
BAHASA
